FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).

Catenacci, Daniel V. T.Kang, Yoon-KooSaeed, AnwaarYamaguchi, KenseiQin, ShukuiLee, Keun-WookKim, In-HoOh, Sang CheulLi, JinTurk, Haci M.Teixeira, Alexandra CarolinaBorg, ChristopheHitre, ErikaUdrea, Anghel AdrianCardellino, Giovanni GerardoGuardeno, RaquelMitra, SiddharthaYang, YingsiEnzinger, Peter C.Wainberg, Zev A.2021-11-302021-11-302021-05-01Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021http://hdl.handle.net/20.500.12645/29666FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).ArticleWOS:00070812060211210.1200/jco.2021.39.15_suppl.4010